viewSeelos Therapeutics

Seelos Therapeutics releases interim study data validating the safety of its ketamine depression drug

It showed 60 milligrams of SLS-002 to be safe and well tolerated as a monotherapy or with an oral antidepressant

Medical worker using tablet and smartphone
More data from the study is expected to be released in the first quarter of 2020, the company said

Seelos Therapeutics Inc (NASDAQ:SEEL) announced promising interim data from a Phase 1 study of its ketamine-based depression treatment. 

The study showed 60 milligrams of Intranasal Racemic Ketamine, known as SLS-002, to be safe and well-tolerated when administered as a monotherapy or in combination with an oral antidepressant. 

“This study is highly encouraging in regard to the side effect profile of SLS-002,” CEO Raj Mehra said in a statement. “We look forward to releasing data throughout the quarter as additional study cohorts are completed and evaluated.” 

READ: Seelos to seek FDA guidance on Phase III trial for SLS-002 ketamine depression drug

The open-label study enrolled 42 healthy volunteers and over two weeks, they received 60mg of SLS-002 and either venlafaxine ER or sertraline. The idea was to evaluate the safety of SLS-002 as well as the drug-drug interaction. 

All adverse events from the study, with one exception, were considered mild or moderate, and all were resolved without medical intervention. 

Seelos previously received Fast Track designation from the US Food and Drug Administration for SLS-002 as a treatment for Acute Suicidal Ideation and Behavior in patients with Major Depressive Disorder.

More data from the study is expected to be released in the first quarter of 2020, the company said.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: Seelos Therapeutics

Price: 0.94 USD

Market: NASDAQ
Market Cap: $33.37 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Seelos Therapeutics named herein, including the promotion by the Company of Seelos Therapeutics in any Content on the Site, the Company...



Seelos Therapeutics rings the Nasdaq opening bell

Seelos Therapeutics Inc (NASDAQ: SEEL) CEO Dr Raj Mehra caught up with Proactive after the clinical-stage biopharmaceutical rung the Nasdaq Stock Market opening bell in Times Square, New York. Dr. Mehra says since listing on the exchange in January, the small company has achieved an...

on 08/12/2019

2 min read